Suppr超能文献

EFSUMB CEUS 胰腺应用指南(2017 年版)诊断性能评估:一项回顾性单中心分析 455 例实性胰腺肿块。

Evaluation of the diagnostic performance of the EFSUMB CEUS Pancreatic Applications guidelines (2017 version): a retrospective single-center analysis of 455 solid pancreatic masses.

机构信息

Department of Ultrasound, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.

Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.

出版信息

Eur Radiol. 2022 Dec;32(12):8485-8496. doi: 10.1007/s00330-022-08879-0. Epub 2022 Jun 14.

Abstract

OBJECTIVES

To explore the diagnostic performance of EFSUMB CEUS Pancreatic Applications guidelines (version 2017) before and after the addition of iso-enhancement and very fast/fast washout as supplementary diagnostic criteria for PDAC.

METHODS

In this retrospective study, patients diagnosed with solid pancreatic lesions from January 2017 to December 2020 were evaluated. Pancreatic ductal adenocarcinoma (PDAC) is reported to show hypo-enhancement in all phases according to the EFSUMB guidelines. First, based on this definition, all lesions were categorized as PDAC and non-PDAC. Then, iso-enhancement and very fast/fast washout were added as supplementary diagnostic criteria, and all lesions were recategorized. The diagnostic performance was assessed in terms of the accuracy (ACC), sensitivity (SEN), specificity (SPE), positive predictive value (PPV), and negative predictive value (NPV). The reference standard consisted of histologic evaluation or composite imaging and clinical follow-up findings.

RESULTS

A total of 455 nodules in 450 patients (median age, 58.37 years; 250 men) were included. The diagnostic performance using the EFSUMB CEUS guidelines for PDAC had an ACC of 69.5%, SEN of 65.4%, SPE of 84%, PPV of 93.5%, NPV of 40.6%, and ROC of 0.747. After recategorization according to the supplementary diagnostic criteria, the diagnostic performance for PDAC had an ACC of 95.8%, SEN of 99.2%, SPE of 84%, PPV of 95.7%, NPV of 96.6%, and ROC of 0.916.

CONCLUSION

The EFSUMB guidelines and recommendations for pancreatic lesions can effectively identify PDAC via hypo-enhancement on CEUS. However, the diagnostic performance may be further improved by the reclassification of PDAC lesions after adding iso-enhancement and very fast/fast washout mode.

KEY POINTS

• In the EFSUMB guidelines, the only diagnostic criterion for PDAC is hypo-enhancement, to which iso-enhancement and very fast/fast washout mode were added in our research. • Using hypo-enhancement/iso-enhancement with very fast/fast washout patterns as the diagnostic criteria for PDAC for solid pancreatic masses on CEUS has high diagnostic accuracy. • The blood supply pattern of PDAC can provide important information, and CEUS has unique advantages in this respect due to its real-time dynamic attenuation ability.

摘要

目的

探讨在补充强化和快速/快速洗脱等补充诊断标准后,EFSUMB 超声造影胰腺应用指南(2017 年版)对 PDAC 的诊断性能。

方法

本回顾性研究评估了 2017 年 1 月至 2020 年 12 月期间诊断为实体性胰腺病变的患者。根据 EFSUMB 指南,胰腺导管腺癌(PDAC)在所有阶段均表现为低增强。首先,根据这一定义,所有病变均分为 PDAC 和非 PDAC。然后,将强化和快速/快速洗脱作为补充诊断标准加入,重新分类所有病变。评估诊断性能的准确性(ACC)、敏感性(SEN)、特异性(SPE)、阳性预测值(PPV)和阴性预测值(NPV)。参考标准包括组织学评估或复合成像和临床随访结果。

结果

共纳入 450 例患者的 455 个结节(中位年龄 58.37 岁;250 例男性)。使用 EFSUMB 超声造影指南诊断 PDAC 的诊断性能为 ACC 为 69.5%,SEN 为 65.4%,SPE 为 84%,PPV 为 93.5%,NPV 为 40.6%,ROC 为 0.747。根据补充诊断标准重新分类后,PDAC 的诊断性能为 ACC 为 95.8%,SEN 为 99.2%,SPE 为 84%,PPV 为 95.7%,NPV 为 96.6%,ROC 为 0.916。

结论

EFSUMB 指南和胰腺病变建议可以通过 CEUS 上的低增强有效识别 PDAC。然而,通过添加同增强和快速/快速洗脱模式重新分类 PDAC 病变后,诊断性能可能会进一步提高。

关键点

  1. 在 EFSUMB 指南中,PDAC 的唯一诊断标准是低增强,我们的研究在此基础上增加了同增强和快速/快速洗脱模式。

  2. 使用 CEUS 上的低增强/同增强伴快速/快速洗脱模式作为实性胰腺肿块 PDAC 的诊断标准具有较高的诊断准确性。

  3. PDAC 的血流供应模式可以提供重要信息,CEUS 具有实时动态衰减能力,在这方面具有独特优势。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验